When and How to Initiate Driving Cessation Conversation for Dementia Patients
40% of people with dementia are still driving.
Alzheimer Disease and Dementia
ALZHEIMER DISEASE AND DEMENTIA
Featured Article
Latest News
Early-Stage Alzheimer Disease Has Adverse Financial Consequences
Robust evidence shows households are at significant risk for large adverse changes in liquid assets.
New Alzheimer Disease Drug to Be Submitted for FDA Approval
New analysis of study results suggests highest dose of aducanumab may help slow cognitive decline.
Hydroxychloroquine Use Not Linked With Risk for Alzheimer Disease
Investigators addressed the association between long-term use of hydroxychloroquine therapy and the risk for Alzheimer disease.
Stepwise Approach Effective for Primary Care Dementia Screening
Stepwise screening starts with a single question on subjective memory loss.
Trial Investigating Pimavanserin for Dementia-Related Psychosis Stopped Early Due to Positive Findings
A phase 3 trial evaluating pimavanserin (Acadia) for the treatment of dementia-related psychosis has been stopped early due to positive findings in a planned interim efficacy analysis.
Hearing Aid Use Tied to Lower Risk for Dementia, Depression, Falls
Use of hearing aids is associated with lower risks for being diagnosed with Alzheimer disease, dementia, depression, anxiety, and injurious falls among elderly adults diagnosed with hearing loss.
Resistance Exercise Can Improve Depression in Patients With Alzheimer Disease, Sarcopenia
Patients with Alzheimer disease who participated in elastic resistance exercises showed changes in depressive symptoms, muscle function, and muscle mass.
Acetylcholinesterase Inhibitors May Reduce Psychotropic Prescriptions in Alzheimer Disease
Use of acetylcholinesterase inhibitors to manage dementia-related behavioral and psychological symptoms in people with Alzheimer disease may reduce the need for psychotropic medications.
Suvorexant Evaluated for Insomnia in Patients With Alzheimer Disease Dementia
Results from a study evaluating the safety and efficacy of suvorexant (Merck) for the treatment of insomnia in patients with mild to moderate Alzheimer disease dementia were presented at the AAN meeting.
Treatment Shows Promise for Agitation in Alzheimer Dementia Patients
Avanir announced data from the phase 3 clinical program that evaluated AVP-786 (deudextromethorphan hydrobromide/quinidine sulfate) for the treatment of moderate-to-severe agitation in patients with Alzheimer dementia.
Want to read more?
Please login or register first to view this content.
Next post in Alzheimer Disease and Dementia
